Kobayashi Pharmaceutical Co., Ltd.: meeting of 27 Mar 2026

Votes reported on Form N-PX, item by item

31 Form N-PX filers reported votes at the Kobayashi Pharmaceutical Co., Ltd. meeting of 27 Mar 2026. Their records fall into 8 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

DIRECTOR ELECTIONSIssuer

Director elections

11 nominees; 91.7% of reported votes for; 16 filers withheld from or voted against at least one nominee.

519 vote records from 31 filers. 0 of the 30 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.

96.8% for0.0% against3.2% other0.0% against management31 filers

DIRECTOR ELECTIONSSecurity holder

Director elections (nominees put forward by security holders)

1 nominee; 0.0% of reported votes for; 2 filers withheld from or voted against at least one nominee.

5 vote records from 3 filers. 0 of the 2 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.

0.0% for0.0% against100.0% other0.0% against management3 filers

COMPENSATIONIssuer

COMPENSATION: management items

Management items in this category are shown together; filers word and number them differently.

96 vote records from 31 filers. 0 of the 30 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.

96.8% for0.0% against3.2% other0.0% against management31 filers98.9% for0.0% against1.1% other0.0% against management5,176,332 reported shares, counted once per item in this group

CORPORATE GOVERNANCEIssuer

CORPORATE GOVERNANCE: management items

Management items in this category are shown together; filers word and number them differently.

57 vote records from 31 filers. 0 of the 30 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.

96.8% for0.0% against3.2% other0.0% against management31 filers99.1% for0.0% against0.9% other0.0% against management3,260,866 reported shares, counted once per item in this group

CORPORATE GOVERNANCESecurity holder

Amend Articles to Add Provision on Product Quality Control and Safety

48 vote records from 31 filers. 2 of the 30 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.

6.5% for90.3% against3.2% other6.7% against management31 filers5.5% for93.4% against1.1% other5.6% against management2,588,166 reported shares

CORPORATE GOVERNANCESecurity holder

Shareholder Proposal Regarding Outside Board Chair

48 vote records from 31 filers. 15 of the 30 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.

48.4% for48.4% against3.2% other50.0% against management31 filers9.2% for89.7% against1.1% other9.3% against management2,588,166 reported shares

CORPORATE GOVERNANCESecurity holder

Amend Articles to Provide Monthly Reports to Outside Directors

48 vote records from 31 filers. 2 of the 30 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.

6.5% for90.3% against3.2% other6.7% against management31 filers5.5% for93.4% against1.1% other5.6% against management2,588,166 reported shares

CORPORATE GOVERNANCESecurity holder

Shareholder proposal: CORPORATE GOVERNANCE

43 vote records from 28 filers. 26 of the 28 filers that marked the item either way voted against management.

0.0% for7.1% against92.9% other92.9% against management28 filers0.0% for27.9% against72.1% other72.1% against management2,416,531 reported shares

How the largest families voted

Family	1. Directors	2. Directors	5. Proposal	6. Proposal	7. Proposal	8. Proposal
Vanguard	For	No report	Against	Against	Against	Abstain or withhold *
BlackRock and iShares	For	No report	Against	Against	Against	Against
Fidelity	For	No report	Against	Against	Against	Abstain or withhold *
State Street and SPDR	For	No report	Against	Against	Against	Abstain or withhold *
Franklin Templeton	For	No report	Against	For *	Against	Abstain or withhold *
Invesco	For	No report	Against	For *	Against	Abstain or withhold *
Equitable	For	No report	Against	For *	Against	Abstain or withhold *
Charles Schwab	For	Abstain or withhold	For *	For *	For *	No report
Nuveen and TIAA	For	No report	Against	Against	Against	Abstain or withhold *
Morgan Stanley, Eaton Vance and Calvert	For	No report	Against	For *	Against	Abstain or withhold *
Goldman Sachs	For	No report	Against	For *	Against	Abstain or withhold *
Northern Trust and FlexShares	For	No report	Against	Against	Against	Abstain or withhold *
BNY Mellon	For	No report	Against	For *	Against	Abstain or withhold *
MFS	For	No report	Against	For *	Against	Abstain or withhold *
PIMCO	For	No report	Against	For *	Against	Abstain or withhold *

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the Kobayashi Pharmaceutical Co., Ltd. meeting?

31 Form N-PX filers reported votes at the meeting of 27 Mar 2026. 4 proposals from security holders could be told apart in the filings. The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Kobayashi Pharmaceutical Co., Ltd. on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for Kobayashi Pharmaceutical Co., Ltd.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Kobayashi Pharmaceutical Co., Ltd. with a meeting date within three days of 27 Mar 2026. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.